Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Lanasa

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Cytometry. Part B, Clinical Cytometry|September 15, 2010
Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detectionWendy G Nieto, Julia Almeida, Cristina Teodosio, et al.
Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Genetic susceptibility variants for chronic lymphocytic leukemiaSusan L Slager, Lynn R Goldin, Sara S Strom, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 12, 2013
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypesSusan L Slager, Sara J Achenbach, Yan W Asmann, et al.
Blood|December 7, 2010
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLLSusan L Slager, Kari G Rabe, Sara J Achenbach, et al.
British Journal of Haematology|August 27, 2010
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL familiesLynn R Goldin, Mark C Lanasa, Susan L Slager, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Cytometry. Part B, Clinical Cytometry|September 15, 2010
Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detectionWendy G Nieto, Julia Almeida, Cristina Teodosio, et al.
Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Genetic susceptibility variants for chronic lymphocytic leukemiaSusan L Slager, Lynn R Goldin, Sara S Strom, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 12, 2013
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypesSusan L Slager, Sara J Achenbach, Yan W Asmann, et al.
Blood|December 7, 2010
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLLSusan L Slager, Kari G Rabe, Sara J Achenbach, et al.
British Journal of Haematology|August 27, 2010
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL familiesLynn R Goldin, Mark C Lanasa, Susan L Slager, et al.
Pageof 4